葡萄糖耐受测试市场规模、份额、成长分析、按产品类型、按适应症、按最终用户、按地区 - 产业预测，2025 年至 2032 年

2023 年全球葡萄糖耐受性测试市场规模价值 272 亿美元，预计将从 2024 年的 288 亿美元成长到 2032 年的 455.7 亿美元，预测期内（2025-2032 年）的复合年增长率为 5.9%。

由于糖尿病盛行率不断上升、技术不断进步以及人们对照护现场（POC）血糖值检测益处的认识不断提高，糖尿病护理市场正在经历显着增长。无针血糖监测设备的推出彻底改变了糖尿病管理，为患者提供了无痛苦的选择。临床和实验室标准协会最近对准确性指南进行了标准化，增强了 POC 测试的可靠性，尤其是在重症加护环境中。 2021年糖尿病患者数量估计为5.37亿，预计2045年将达到7.83亿。对葡萄糖诊断和快速检测（STAT）解决方案的不断增长的需求反映了医疗保健行业对改善患者照护、管理血糖浓度的效率和依从性的关注。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管格局
• 案例研究
• 技术进步

葡萄糖耐受性测试市场规模（依产品类型）

• 市场概况
• 智慧感测器
• 血糖值检测套组
• 米
• 测试纸
• 其他的

葡萄糖耐受性测试市场规模（按疾病类型划分）

• 市场概况
• 反应性低血糖
• 糖尿病低血糖
• 妊娠糖尿病
• 胰岛素抗性
• 其他的

葡萄糖耐受性测试市场规模（按最终用户划分）

• 市场概况
• 医院
• 诊所
• 诊断中心
• 其他的

葡萄糖耐受性测试市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• Thermo Fisher Scientific Inc.（United States）
• Medtronic（United States）
• NIPRO（Japan）
• Trividia Health, Inc.（United States）
• Dexcom, Inc.（United States）
• Healius Limited（Australia）
• Penlan Healthcare Ltd.（United Kingdom）
• Quest Diagnostics Incorporated（United States）
• Johnson & Johnson Services, Inc.（United States）
• Abbott（United States）
• Laboratory Corporation of America Holdings（United States）
• ARUP Laboratories（United States）
• Cleveland HeartLab, Inc.（United States）
• Merck KGaA（Germany）
• Bayer AG（Germany）
• Ascensia Diabetes Care Holdings AG（Switzerland）
• E-Zlab Health Services（Canada）
• F. Hoffman-La Roche Ltd（Switzerland）
• LifeScan IP Holdings, LLC（United States）
• Sanofi（France）

结论和建议

Global Glucose Tolerance Test Market size was valued at USD 27.2 billion in 2023 and is poised to grow from USD 28.8 billion in 2024 to USD 45.57 billion by 2032, growing at a CAGR of 5.9% during the forecast period (2025-2032).

The market for diabetes care is experiencing significant growth, driven by increasing diabetes prevalence, technological advancements, and heightened awareness of point-of-care (POC) glucose testing benefits. The introduction of needle-free blood glucose monitoring devices is revolutionizing diabetes management, offering patients a painless alternative. Recent standardization of accuracy guidelines by the Clinical & Laboratories Standard Institute bolsters the reliability of POC testing, especially in critical care environments. With an estimated 537 million people living with diabetes in 2021, forecast projections suggest this number could reach 783 million by 2045. The rising demand for glucose diagnostics and Short Turn-Around Testing (STAT) solutions reflects the healthcare sector's focus on improved patient care, efficiency, and compliance in managing glucose levels.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Glucose Tolerance Test market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Glucose Tolerance Test Market Segmental Analysis

Global Glucose Tolerance Test Market is segmented by Product Type, Disease Indication, End user and region. Based on Product Type, the market is segmented into Smart Sensors, Blood Glucose Testing Kit, Meters, Test Slips and Others. Based on Disease Indication, the market is segmented into Reactive Hypoglycemia, Diabetes Hypoglycemia, Gestational Diabetes, Insulin Resistance and Others. Based on End user, the market is segmented into Hospitals, Clinics, Diagnostic Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Glucose Tolerance Test Market

The global glucose tolerance test market is significantly driven by the escalating prevalence of diabetes across the globe. Factors contributing to this alarming rise include lifestyle alterations, such as decreased physical activity and unhealthy dietary choices, which in turn amplify the demand for reliable diagnostic tools like glucose tolerance tests. As the awareness surrounding diabetes continues to grow, so does the popularity of these tests, owing to their essential role in the early detection and management of the condition. Consequently, the increasing diabetes rates are compelling healthcare providers and patients alike to prioritize the utilization of glucose tolerance testing, propelling the market forward.

Restraints in the Global Glucose Tolerance Test Market

The global glucose tolerance test market faces significant constraints primarily due to the high costs associated with testing. Many individuals, particularly in economically disadvantaged regions, find these expenses prohibitive, which can lead to a reluctance to undergo essential diagnostic procedures. The financial burden stems from the prices of glucose testing kits, meters, and necessary accessories, along with the frequency of testing required to monitor glucose levels effectively. This situation may hinder market growth by discouraging patients from seeking vital testing services, ultimately affecting overall public health and the early detection of diabetes and related conditions.

Market Trends of the Global Glucose Tolerance Test Market

The Global Glucose Tolerance Test (GTT) market is experiencing significant growth due to advancing diagnostic technologies and increasing diabetes prevalence. As global populations age and unhealthy lifestyle choices rise, there is a marked increase in cases of diabetes and prediabetes, driving the demand for accurate diagnostic tools. Healthcare policies are also evolving to prioritize early intervention, highlighting the necessity for effective screening methods like the GTT. This burgeoning market is fueled by continual innovations in testing methodologies and an urgent need for reliable diagnostics, positioning GTT as a critical component in diabetes management strategies worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Glucose Tolerance Test Market Size by Product Type & CAGR (2025-2032)

• Market Overview
• Smart Sensors
• Blood Glucose Testing Kit
• Meters
• Test Slips
• Others

Global Glucose Tolerance Test Market Size by Disease Indication & CAGR (2025-2032)

• Market Overview
• Reactive Hypoglycemia
• Diabetes Hypoglycemia
• Gestational Diabetes
• Insulin Resistance
• Others

Global Glucose Tolerance Test Market Size by End user & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Diagnostic Centers
• Others

Global Glucose Tolerance Test Market Size & CAGR (2025-2032)

• North America (Product Type, Disease Indication, End user)
  • US
  • Canada
• Europe (Product Type, Disease Indication, End user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Disease Indication, End user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Disease Indication, End user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Disease Indication, End user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Thermo Fisher Scientific Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NIPRO (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Trividia Health, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dexcom, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Healius Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Penlan Healthcare Ltd. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics Incorporated (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Laboratory Corporation of America Holdings (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ARUP Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cleveland HeartLab, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ascensia Diabetes Care Holdings AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• E-Zlab Health Services (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffman-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LifeScan IP Holdings, LLC (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations